Andrew John Proudfoot

Mr. Andrew John Proudfoot

Western Sydney University, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
JSJustin Sinclair
Justin Sinclair
SASusanne Armour
Susanne Armour
JAJones Asafo Akowuh
Jones Asafo Akowuh
APAndrew John Proudfoot
Andrew John Proudfoot
Mike ArmourMike Armour
Mike Armour
Objective: This study sought to investigate the perceptions, barriers, and drivers associated with medicinal cannabis use among Australian women with primary dysmenorrhea. A qualitative study via virtual focus groups involving 26 women experiencing regular, moderate, or greater menstrual pain explored categories including cost, associated stigma, current drug driving laws, community and workplace ethics, and geographical isolation within the context of patient access under current Australian laws and regulations. Results: A qualitative descriptive analysis identified that dissatisfaction with current management strategies such as over-the-counter analgesic usage was the key driver for wanting to use medicinal cannabis. A number of significant barriers to use were identified including patient access to medical prescribers, medical practitioner bias, current drug driving laws, geographic location, and cost. Community and cultural factors such as the history of cannabis as an illicit drug and the resulting stigma, even when prescribed by a medical doctor, still existed and was of concern to our participants. Conclusion: Whilst medicinal cannabis is legal in all states and territories within Australia, several barriers to access exist that require government regulatory attention to assist in increasing patient adoption, including possible subsidisation of cost. The high cost of legal, medicinal cannabis was a key factor in women’s choice to use illicit cannabis. Overall, the concerns raised by our participants are consistent with the broader findings of a recent Australian Senate inquiry report into barriers to patient access to medicinal cannabis in Australia, suggesting many of the issues are systematic rather than disease-specific. Given the interest in use of medicinal cannabis amongst women with primary dysmenorrhea, clinical trials in this area are urgently needed.

28 February 2024 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
APAndrew John Proudfoot
Andrew John Proudfoot
SDSarah Duffy
Sarah Duffy
JSJustin Sinclair
Justin Sinclair
JAJason Anthony Abbott
Jason Anthony Abbott
Mike ArmourMike Armour
Mike Armour
People with endometriosis use cannabis to manage their symptoms. This study aimed to identify costs, modes of administration, product composition, and self‐reported effectiveness for those accessing medicinal cannabis in Australia. There were 192 survey responses analysed. Most (63.5%) used a ‘cannabis clinic’ doctor, incurring an initial consultation cost of $100–$200+ (10.2% Medicare bulk‐billed) and median cannabinoid medicine costs of $300AUD per month. Cost was a major barrier to access, necessitating reducing dosage (76.1%) and/or consuming illicit cannabis (42.9%), despite a prescription. Most (77%) medical consumers used two or more cannabis products, with delta‐9‐tetrahydrocannabinol predominant oil and flower products most frequently prescribed.

2 August 2026 in Australian Journal of Human Rights
Verified
Journal Article
Open access
APAndrew John Proudfoot
Andrew John Proudfoot
JSJustin Sinclair
Justin Sinclair
SDSarah Duffy
Sarah Duffy
RMRob Mężyk
Rob Mężyk
Mike ArmourMike Armour
Mike Armour
Insurance medicine, as a field, makes health-related assessments—covering diagnosis, prognosis and the effectiveness of interventions—within the context of life and health insurance to support evid...

12 February 2025 in OSF Preprints
Verified
Preprint
Open access
APAndrew John Proudfoot
Andrew John Proudfoot
MAMike Armour
Mike Armour
SDSarah Duffy
Sarah Duffy
JSJustin Sinclair
Justin Sinclair
People with endometriosis in Australia predominantly use delta-9 tetrahydrocannabinol cannabis flower and oil products, and cannabidiol preparations, to manage their symptoms, reporting reductions in use of other drugs. It is known that lower rates of systematic disclosure of risk factors in life insurance settings, particularly of smoked tobacco, can have an impact on customer premiums, contract terms and claims outcomes, however less is known about cannabis (such as ‘smoker’ or other loadings, exclusions and coverage refusals). This article examines positive and negative risks around disclosure of cannabis use for endometriosis management, from insureds to insurers, when purchasing or increasing life, disability or trauma insurance, in a cohort of Australians. Better condition management and reduced alcohol, tobacco and other drug consumption suggested improved insurability outcome factors relevant to endometriosis and these insurances. Disclosure behaviour however, suggested significant legal risks for insurers and insureds, as misrepresentations and fraudulent non-disclosure of cannabis use occurred. The study outcomes revealed important insurance medicine medico-legal and human rights considerations for insureds and life insurers in the context of certain disclosure behaviours and the legal basis to discriminate relevant to the limited actuarial or statistical data that exists about medical cannabis as an anodyne for endometriosis disease.